|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Ignyta, Inc.
| | | Phone: | (858) 255-5959 | Year Established: | 2011 | Ticker: | RXDX | Exchange: | NASDAQ | Main Contact: | Jacob Chacko, M.D., CFO | | Other Contacts: | William Mccarthy, CBO Valerie Harding, Senior VP, Chemistry, Manufacturing & Controls Bernard Parker, CCO Adrian Senderowicz, M.D., Clinical & Regulatory Strategy Officer Zachary Hornby, COO Robert Shoemaker, Ph.D., Director of Bioinformatics Dave Matthews, Ph.D., Head of Crystallography Paul Pearson, Ph.D., Head of PK, Drug Metabolism & Safety David W. Anderson, Ph.D., VP, Biology Jean-Michel Vernier, Ph.D., VP, Medicinal Chemistry Dr. Christian V. Kuhlen, General Counsel Robert Wild, Ph.D., CSO & Senior VP, Research Pratik Multani, M.D., M.S., CMO Jonathan E. Lim, M.D., Chairman, CEO & Co-Founder
| | Company Description | Ignyta is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Their goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients.The company's present focus is on the development of RXDX-101 and RXDX-102, their proprietary oral tyrosine kinase inhibitors that target solid tumor indications, and advancing our novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases.
On Dec. 22, 2017, Roche and Ignyta announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. | |
|
|
|